Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

The protein tyrosine phosphatase SHP2 binds to phosphorylated signaling motifs on
regulatory immunoreceptors including PD-1, but its functional role in tumor immunity is …

SHP2 is a ubiquitous tyrosine phosphatase involved in regulating both tumor and immune
cell signaling. In this study, we discovered a novel immune modulatory function of SHP2 …

Background: Mutations in KRAS are among the most common aberrations in cancer.
However, despite considerable research efforts, KRAS remains a challenging therapeutic …

Purpose: Human leukocyte antigen (HLA) class I antigen processing machinery (APM)
component downregulation permits escape of malignant cells from recognition by cytotoxic T …

FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …

RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …

Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) is a major phosphatase
involved in several cellular processes. In recent years, SHP2 has been the focus of …

Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its
bidirectional role in both tumor growth promotion and T-cell inactivation. Its allosteric …